Biogen enters CNS R&D collaboration with Rodin with option to buy company; later ends deal
Biogen Inc., concurrent with a $17.3mm co-investment it made with Atlas Venture in Rodin Therapeutics Inc., is collaborating with the start-up to develop epigenetic modulators for CNS disorders.
- Drug Discovery Technologies
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.